B4GALT1 and neoplasm: Additionally, we will test combination regimens with gemcitabine—given B4GALT1’s role in chemoresistance—and with checkpoint blockade (anti–PD-1/PD-L1), to explore potential synergy in overcoming the immunosuppressive tumor microenvironment typical of PDAC.